PL2438087T3 - Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych - Google Patents

Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych

Info

Publication number
PL2438087T3
PL2438087T3 PL10724497T PL10724497T PL2438087T3 PL 2438087 T3 PL2438087 T3 PL 2438087T3 PL 10724497 T PL10724497 T PL 10724497T PL 10724497 T PL10724497 T PL 10724497T PL 2438087 T3 PL2438087 T3 PL 2438087T3
Authority
PL
Poland
Prior art keywords
hrsv
prevention
treatment
syncytial virus
tract infections
Prior art date
Application number
PL10724497T
Other languages
English (en)
Inventor
Erik Depla
Catelijne Stortelers
Stephanie Staelens
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of PL2438087T3 publication Critical patent/PL2438087T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10724497T 2009-06-05 2010-06-07 Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych PL2438087T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18439609P 2009-06-05 2009-06-05
US26501409P 2009-11-30 2009-11-30
PCT/EP2010/057921 WO2010139808A2 (en) 2009-06-05 2010-06-07 IMPROVED AMINO ACID SEQUENCES DIRECTED AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (hRSV) AND POLYPEPTIDES COMPRISING THE SAME FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS
EP10724497.2A EP2438087B1 (en) 2009-06-05 2010-06-07 Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections

Publications (1)

Publication Number Publication Date
PL2438087T3 true PL2438087T3 (pl) 2017-10-31

Family

ID=42333502

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10724497T PL2438087T3 (pl) 2009-06-05 2010-06-07 Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych

Country Status (25)

Country Link
US (3) US8945567B2 (pl)
EP (2) EP3205670A1 (pl)
JP (2) JP6081196B2 (pl)
KR (1) KR101852204B1 (pl)
CN (2) CN105061592A (pl)
AU (1) AU2010255638B2 (pl)
BR (1) BRPI1010830A2 (pl)
CA (1) CA2764398A1 (pl)
CY (1) CY1119265T1 (pl)
DK (1) DK2438087T3 (pl)
ES (1) ES2643034T3 (pl)
HR (1) HRP20171194T1 (pl)
HU (1) HUE035773T2 (pl)
IL (1) IL216341A0 (pl)
LT (1) LT2438087T (pl)
MX (1) MX340541B (pl)
NZ (1) NZ597314A (pl)
PH (1) PH12019500644A1 (pl)
PL (1) PL2438087T3 (pl)
PT (1) PT2438087T (pl)
RU (2) RU2577134C2 (pl)
SG (1) SG176095A1 (pl)
SI (1) SI2438087T1 (pl)
WO (1) WO2010139808A2 (pl)
ZA (1) ZA201108892B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
MX340541B (es) 2009-06-05 2016-07-13 Alblynx Nv Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
EP2533761B1 (en) 2010-02-11 2019-03-27 Ablynx N.V. Methods and compositions for the preparation of aerosols
WO2012056000A1 (en) 2010-10-29 2012-05-03 Ablynx Nv Method for the production of immunoglobulin single variable domains
EP3590950A1 (en) 2011-05-09 2020-01-08 Ablynx NV Method for the production of immunoglobulin single varible domains
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
PL2968520T3 (pl) 2013-03-14 2022-01-03 Macrogenics, Inc. Dwuspecyficzne cząsteczki, które są immunoreaktywne wobec immunologicznych komórek efektorowych wykazujących ekspresję receptora aktywującego
CN105636936B (zh) 2013-08-21 2022-04-05 詹森生物制药有限公司 抗病毒化合物
SG11201700851WA (en) * 2014-08-05 2017-03-30 Alios Biopharma Inc Combination therapy for treating a paramyxovirus
CA2963991A1 (en) 2014-09-29 2016-04-07 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
SG11201702688UA (en) * 2014-10-10 2017-04-27 Ablynx Nv Methods of treating rsv infections
HUE044199T2 (hu) 2014-10-10 2019-10-28 Ablynx Nv Inhalációs készülék légúti betegségek aeroszolos terápiájában való alkalmazásra
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
EP3313432A1 (en) * 2015-06-18 2018-05-02 VIB vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
EP3124042A1 (en) * 2015-07-28 2017-02-01 VIB, vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
CN109311968A (zh) 2016-05-02 2019-02-05 埃博灵克斯股份有限公司 治疗rsv感染
WO2017220645A1 (en) 2016-06-23 2017-12-28 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
CN106279410B (zh) * 2016-09-29 2019-08-20 华南理工大学 一种二型登革热病毒ns1蛋白多价纳米抗体及制备方法
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
AU2017345786B2 (en) 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
BR112019008063A2 (pt) 2016-10-21 2019-07-02 Adimab Llc anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
US11725045B2 (en) 2017-10-13 2023-08-15 Mapp Biopharmaceutical, Inc. Anti-respiratory syncytial virus antibodies, methods of their generation and use
JP7123607B2 (ja) * 2018-04-09 2022-08-23 シャープ株式会社 ユーザ装置、制御装置、及び通信制御方法
KR20210150509A (ko) 2019-04-10 2021-12-10 리제너론 파마슈티칼스 인코포레이티드 Ret에 결합하는 인간 항체 및 그것의 사용 방법
CN111748571B (zh) * 2019-10-11 2022-05-03 浙江禾霖生物科技有限公司 一种将枯草芽孢杆菌工程化为生产纳米抗体的多功能稳定平台的方法
IL293282A (en) 2019-11-25 2022-07-01 Mabloc Llc Yellow fever antiviral antibodies and methods of making and using them
US20210230248A1 (en) * 2020-01-25 2021-07-29 Jun Chen Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
CN116693673B (zh) * 2023-07-26 2023-10-20 中国人民解放军军事科学院军事医学研究院 广谱抗SARS和SARS-CoV-2的纳米抗体、多价纳米抗体及其应用

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1120945A (en) 1964-08-11 1968-07-24 Fisons Pharmaceuticals Ltd Applicator in combination with a pressurised aerosol dispensing container
WO1990004788A1 (en) 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991015581A1 (en) 1990-04-05 1991-10-17 Roberto Crea Walk-through mutagenesis
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2137558A1 (en) 1992-07-17 1994-02-03 Wayne A. Marasco Method of intracellular binding of target molecules
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
ATE198490T1 (de) 1993-06-09 2001-01-15 Unilever Nv Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
ATE400651T1 (de) 1993-09-10 2008-07-15 Univ Columbia Verwendung von grünem fluoreszenzprotein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en) 1995-05-05 1997-12-02 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP0851874B1 (en) 1995-09-22 1999-09-15 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
CA2270288A1 (en) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Human monoclonal antibodies
WO1998021355A1 (en) 1996-11-15 1998-05-22 Life Technologies, Inc. Mutants of green fluorescent protein
WO1998022141A2 (en) 1996-11-19 1998-05-28 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
FR2766826B1 (fr) 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
EP1469883A2 (en) 1998-02-19 2004-10-27 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
AU779162B2 (en) 1999-02-05 2005-01-06 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
OA11862A (en) 1999-04-22 2006-03-02 Unilever Nv Inhibition of viral infection using monovalent antigen-binding proteins.
CO5280147A1 (es) 1999-05-18 2003-05-30 Smithkline Beecham Corp Anticuerpo humano monoclonal
IL147920A0 (en) 1999-08-02 2002-08-14 Keygene Nv Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
PT1240337E (pt) 1999-12-24 2007-01-31 Genentech Inc Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7054297B1 (en) 2000-12-28 2006-05-30 Cisco Technology, Inc. Distribution of packets to high data rate communications devices using multicast protocols
CA2433877C (en) 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002355477B2 (en) 2001-08-03 2008-09-25 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
FR2829940A1 (fr) 2001-09-27 2003-03-28 Synt Em Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP2005516939A (ja) 2001-12-18 2005-06-09 イノジェネティックス・ナムローゼ・フェンノートシャップ 診断及び治療用途の精製ｃ型肝炎ウイルス外被タンパク質
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
BRPI0316092B8 (pt) 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1578842B1 (en) 2002-12-31 2009-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP2390270A1 (en) 2003-01-10 2011-11-30 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US7070786B2 (en) 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
US20050136428A1 (en) 2003-06-27 2005-06-23 Roberto Crea Look-through mutagenesis
PT1639011E (pt) 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
WO2005001690A2 (de) 2003-06-30 2005-01-06 Siemens Aktiengesellschaft Verfahren zur überwachung des programmlaufs in einem mikro-computer
AU2003264053A1 (en) 2003-08-12 2005-03-10 William M. Yarbrough Treatment for acne vulgaris and method of use
EP1512696A1 (en) 2003-08-14 2005-03-09 Diatos Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
US20050288491A1 (en) 2004-02-17 2005-12-29 Wilson David S Super-humanized antibodies against respiratory syncytial virus
US7207410B2 (en) 2004-04-29 2007-04-24 Daimlerchrysler Corporation Apparatus and method for enhanced impact sensing
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
ES2372503T3 (es) 2004-07-06 2012-01-20 Bioren, Inc. Mutagénesis revisada para desarrollar polipéptidos alterados con propiedades potenciadas.
US7180370B2 (en) 2004-09-01 2007-02-20 Micron Technology, Inc. CMOS amplifiers with frequency compensating capacitors
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
US20060115485A1 (en) 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
WO2006059108A2 (en) * 2004-12-02 2006-06-08 Domantis Limited ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
JP5011277B2 (ja) 2005-04-06 2012-08-29 アイビーシー・ファーマシューティカルズ・インコーポレーテッド ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用
AU2006234847A1 (en) 2005-04-08 2006-10-19 Medimmune, Llc Antibodies against mammalian metapneumovirus
MX342271B (es) 2005-05-18 2016-09-21 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
EP2086998B1 (en) 2006-10-11 2011-12-07 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof
AU2007310838A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
EP2097449A1 (en) 2006-12-05 2009-09-09 Ablynx N.V. Peptides capable of binding to serum proteins
EP2097451A2 (en) 2006-12-22 2009-09-09 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
WO2009004065A2 (en) 2007-07-03 2009-01-08 Ablynx N.V. Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
EP2096121A1 (en) 2008-02-29 2009-09-02 Institut Pasteur Of Shanghai Antiviral peptides comprising lipid attachment signals and methods of use
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
ES2701649T3 (es) 2009-01-14 2019-02-25 Ablynx Nv Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos
PL2424889T3 (pl) 2009-04-30 2016-01-29 Ablynx Nv Sposób wytwarzania przeciwciał domenowych
MX340541B (es) 2009-06-05 2016-07-13 Alblynx Nv Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections

Also Published As

Publication number Publication date
CN102459332A (zh) 2012-05-16
RU2577134C2 (ru) 2016-03-10
US20150118233A1 (en) 2015-04-30
JP6081196B2 (ja) 2017-03-01
SG176095A1 (en) 2011-12-29
SI2438087T1 (sl) 2017-10-30
JP6677659B2 (ja) 2020-04-08
MX2011013013A (es) 2012-01-30
RU2016103067A (ru) 2018-11-20
KR20140015113A (ko) 2014-02-06
AU2010255638B2 (en) 2014-10-16
CA2764398A1 (en) 2010-12-09
US9803001B2 (en) 2017-10-31
US8945567B2 (en) 2015-02-03
CN105061592A (zh) 2015-11-18
KR101852204B1 (ko) 2018-04-26
CY1119265T1 (el) 2018-02-14
NZ597314A (en) 2013-07-26
RU2016103067A3 (pl) 2019-08-08
BRPI1010830A2 (pt) 2023-11-14
MX340541B (es) 2016-07-13
HRP20171194T1 (hr) 2017-10-20
US20120128669A1 (en) 2012-05-24
EP3205670A1 (en) 2017-08-16
CN102459332B (zh) 2015-08-19
AU2010255638A1 (en) 2012-01-12
PH12019500644A1 (en) 2020-10-12
ZA201108892B (en) 2013-05-29
HUE035773T2 (en) 2018-05-28
PT2438087T (pt) 2017-08-04
IL216341A0 (en) 2012-01-31
WO2010139808A3 (en) 2011-02-24
US20180105581A1 (en) 2018-04-19
LT2438087T (lt) 2017-08-25
EP2438087B1 (en) 2017-05-10
JP2017093460A (ja) 2017-06-01
DK2438087T3 (en) 2017-08-28
WO2010139808A2 (en) 2010-12-09
US11028151B2 (en) 2021-06-08
EP2438087A2 (en) 2012-04-11
JP2012528584A (ja) 2012-11-15
ES2643034T3 (es) 2017-11-21
RU2011153239A (ru) 2013-07-20

Similar Documents

Publication Publication Date Title
PT2438087T (pt) Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório
HK1172350A1 (zh) 針對人呼吸道合胞病毒 的抗體以及使用方法
HK1199607A1 (en) Human milk oligosaccharides for preventing injury and or promoting healing of the gastrointestinal tract
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
HK1196131A1 (zh) 用於治療或預防呼吸道合胞病毒疾病的化合物
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
IL227193B (en) Plant extracts for the treatment and prevention of inflammation
EP2349140A4 (en) DEVICES, SYSTEMS AND METHODS FOR TREATING SLEEP APNEA
IL200330A0 (en) Recombinant antibodies for treatment of respiratory syncytial virus infections
GB2496794B (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
ZA201209289B (en) Urea derivatives and their therapeutic use in the treatment of,inter alia,diseases of the respiratory tract
EP2427061A4 (en) GALLIUM FORMULATION FOR THE TREATMENT AND PROPHYLAXIS OF INFECTION DISEASES
EP2651439A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HUMAN ADENOVIRUS 36 INFECTION
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
GB2496800B (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
EP2521554A4 (en) SUBSTANCES AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS
HK1197058A1 (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
EP2222258A4 (en) SYSTEMS AND METHOD FOR HEAT TREATMENT OF BODY TISSUE
EP2361317A4 (en) USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER
PT2895180T (pt) Composição para a prevenção e o tratamento de infeções agudas e recorrentes do trato urinário
PL2508192T3 (pl) Środek do leczenia i profilaktyki chorób męskiego układu moczowo-płciowego
HK1188565A1 (en) Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans
EP2160191A4 (en) SUPPRESSION OF VIRUSES INVOLVED IN A DISEASE OR RESPIRATORY INFECTION
SI2315580T1 (sl) Farmacevtski pripravki in postopki za zdravljenjeinfekcij respiratornega trakta
ZA201400442B (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease